Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.12% | -26.76% | -19.71% | 9.19% | -148.67% |
| Total Depreciation and Amortization | 50.00% | -100.00% | -50.00% | 473.33% | -9.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.97% | 70.23% | 496.89% | -123.88% | 586.03% |
| Change in Net Operating Assets | 149.38% | 370.34% | -703.88% | -190.67% | 3.84% |
| Cash from Operations | -27.42% | -13.21% | -33.42% | -201.13% | -8.61% |
| Capital Expenditure | -- | 0.00% | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -218.15% | 325.45% | -- | 35.54% | -- |
| Cash from Investing | -218.17% | 325.94% | -- | 35.54% | 173,086.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 311.76% | 11,500.00% | -- | 1,515.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 408.49% | -- |
| Cash from Financing | 311.76% | 11,500.00% | -- | 8,667.32% | 111.29% |
| Foreign Exchange rate Adjustments | -150.82% | 296.75% | 102.59% | 126.13% | -73.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -285.22% | 318.19% | -5.07% | 249.91% | 406.81% |